The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes

Cardiovascular Drugs and Therapy

Volumn 22, Issue 3, 2008, Pages 207-213

  Kar, Partha ^a   Holt, Richard I G ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Macrovascular complications; Microvascular complications; Sulphonylurea; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BIGUANIDE; CD31 ANTIGEN; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; GLUTATHIONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; MEGLITINIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; POLYOL; POTASSIUM CHANNEL; PROTEIN KINASE C BETA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN;

ARTICLE; CALCIUM SIGNALING; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIABETIC MICROANGIOPATHY; DRUG MECHANISM; DYSLIPIDEMIA; GLUCOSE HOMEOSTASIS; GLYCATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSULIN RELEASE; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; THROMBOCYTE ACTIVATION; WEIGHT GAIN;

ANIMALS; DIABETIC ANGIOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; MICROCIRCULATION; SULFONYLUREA COMPOUNDS;

EID: 48349104113     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-008-6090-2     Document Type: Article

References (31)

1. Forouhi NG, Merrick D, Goyder E, Ferguson BA, Abbas J, Lachowycz K, Wild SH. Diabetes prevalence in England, 2001-estimates from an epidemiological model. Diabet Med 2006;23:189-97.
2. Janbon M, Chaptal J, Vedel A, Schaap J. Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montpellier Med 1942;441:21-2.
3. Patlak M. New Weapons to Combat an Ancient Disease: Treating Diabetes. FASEB J 2002;16:1853E.
4. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2007.
5. Stratton I, Adler A, Neil A, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
6. Brunner E, Shipley M, Witte D, et al. Relation between blood glucose and coronary mortality over 33 years in the Whitehall study. Diabetes Care 2006;29:26-31.
7. Gerstein H. Dysglycaemia: a cardiovascular risk factor. Diabetes Res Clin Pract 1998;40:9-14.
8. The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Diabetes Med 2000;26:282-6. (Sep).
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
10. Pedersen O, Gæde PH. Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2-study. Metabolism 2003;52:19-23.
11. Holman R. Long term efficacy of sulphonylureas. Metab Clin Exp 2006;55:S2-5.
12. Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996;39:503-14.
13. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-7.
14. Pagano PJ, Griswold MC, Ravel D, Cohen RA. Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. Diabetologia 1998;41:9-15.
15. Okouchi M, Okayama N, Omi H, et al. The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium. Diabetes Metab Res Rev 2004;20:232-8.
16. Zaremba J, Losy J. sPECAM-1in serum and CSF of acute ischaemic stroke patients. Acta Neurol Scand 2002;106:292-8.
17. Soeki T, Tamura Y, Shinohara H, Sakabe K, Onose Y, Fukuda N. Increased sPECAM-1in the early stages of acute coronary syndromes. Int J Cardiol 2003;90:261-8.
18. Katakami N, Yamasaki Y, Hayaishi-Okano R, et al. Metformin or gliclazide, rather than glibenclamide, attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Diabetologia 2004;47:1906-13.
19. U.K Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
20. Meinert CL, Knatterud GL, Prout TE, et al. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789-830.
21. Simpson S, Majumdar S, Tsuyuki RT, Eurich D, Johnson J. Dose-response relation between sulphonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:2. (January 17).
22. Deutsch E, Berger M, Kussmaul WG, Hirschfeld JW Jr, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolid features. Circulation 1990;82:2044-51.
23. Kloner RA, Yellon D. Does ischemic preconditioning occur in patients? J Am Coll Cardiol 1994;24:1133-42.
24. ATP channels in preconditioning. Circ Res 2000;87:845-55.
25. ATP channels. Physiol Rev 1998;78:227-45.
26. Lazdunski M. Ion channel effects of antidiabetic sulfonylureas. Horm Metab Res 1996;28:488-95.
27. Ashcroft FM. Mechanisms of the glycaemic effects of sulfonylureas. Horm Metab Res 1996;28:456-63.
28. Riddle M. Editorial: Sulphonylureas differ in effects on ischaemic preconditioning-is it time to retire Glyburide? J Clin Endocrinol Metab 2003;88:528-30.
29. Lee TM, Chou TF. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003;88:531-7.
30. Cacciapuoti F, Spiezia S, Bianchi U, Lama D, D'avino M, Varricchio M. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. Am J Cardiol 1991;67:843-47.
31. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61.